Quidel Corporation
318 articles about Quidel Corporation
-
Development of New Drugs to Target Lyme and Other Infectious Diseases Subject of a New Webinar Now Available From Quidel Corporation
10/4/2022
Lyme disease is the fastest-growing vector-borne disease in the United States, and its increased prevalence is challenging the scientific community to look for new ways to diagnose and treat this worrisome infection.
-
QuidelOrtho Formed by the Completion of Transaction Combining Quidel and Ortho Clinical Diagnostics
5/27/2022
QuidelOrtho Corporation (NASDAQ: QDEL) (“QuidelOrtho”) announced completion of the transaction combining Quidel Corporation (“Quidel”) and Ortho Clinical Diagnostics Holdings plc (“Ortho”), creating QuidelOrtho, a leading in vitro diagnostics company.
-
Quidel and Ortho Announce Expected Closing of Ortho Transaction
5/26/2022
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, and Ortho Clinical Diagnostics Holdings plc (“Ortho”), one of the world’s larger pure-play in vitro diagnostics companies, announced today that the closing of the previously announced Ortho transaction is expected to occur on May 27, 2022.
-
Quidel Announces Stockholder Approval of Ortho Acquisition and Business Combination
5/16/2022
Quidel Corporation announced that the previously announced acquisition of Ortho Clinical Diagnostics Holdings plc by Quidel and subsequent business combination were approved by Quidel’s stockholders at Quidel’s Special Meeting on May 16, 2022.
-
Ortho Clinical Diagnostics Shareholders Approve Quidel Transaction
5/16/2022
Ortho Clinical Diagnostics Holdings plc announced that based on a preliminary vote count by its proxy solicitor, Ortho shareholders have voted to approve the combination of the Company with Quidel Corporation pursuant to the Business Combination Agreement, dated December 22, 2021, by and among the Company, Quidel, and the other parties thereto.
-
Quidel Reports First Quarter 2022 Financial Results
5/4/2022
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the first quarter ended March 31, 2022.
-
Quidel to Hold Fiscal First Quarter 2022 Financial Results Conference Call on May 4th, 2022
4/12/2022
Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fiscal first quarter 2022 financial results after market close on Wednesday, May 4, 2022.
-
Quidel Announces Preliminary Revenue for First Quarter 2022
4/7/2022
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects total revenues in the first quarter of 2022 to be in the range of $990 million to $1,000 million, or growth of 164% to 166% from the first quarter 2021 revenue of $375.3 million.
-
Quidel to Present at Raymond James 43rd Annual Institutional Investors Conference
2/28/2022
Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the Raymond James & Associates 43rd Annual Institutional Investors Conference.
-
Quidel Announces Preliminary Revenue for Fourth Quarter 2021
1/6/2022
Quidel Corporation, a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced that it expects total revenues in the fourth quarter of 2021 to be in the range of $633 million to $637 million and full year total revenues to be in the range of $1,695 million to $1,699 million.
-
The Signs, Diagnosis and Treatment of Lyme Disease Discussed as Part of New, On-Demand Webinar Hosted by Industry-Leading Quidel Corporation
1/5/2022
An important public health webinar focused on the Bartonella species, the bacterium that causes Bartonellosis, is now available on demand at https://education.quidel.com/educational-categories.
-
Quidel to Present at 40th Annual J.P. Morgan Healthcare Conference
1/4/2022
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cell-based virology assays and molecular diagnostic systems, announced today that it will present at the 40th Annual J.P. Morgan Healthcare Conference to be held virtually on Wednesday, January 12, 2022.
-
Quidel’s Antigen Tests Detect the Omicron Variant
12/28/2021
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, issued the following statement from Douglas Bryant, Quidel’s President and CEO, regarding Quidel’s ongoing efforts to evaluate COVID-19 mutations and confirm that its antigen tests continue to detect COVID-19 variants such as Omicron.
-
Quidel Corporation Signs Definitive Agreement to Acquire Ortho Clinical Diagnostics
12/23/2021
Quidel Corporation today announced that they have entered into a definitive agreement in which Quidel will acquire Ortho.
-
Series of Infographics From Quidel Corporation Helps Educate Consumers on the Characteristics, Warning Signs and Prevalence of Lyme Disease
12/14/2021
With Lyme disease being identified in record numbers throughout the country, a series of consumer-friendly infographics has been released by Quidel to help educate Americans on its characteristics, warning signs, seasonality and areas of prevalence.
-
Quidel Statement on the Omicron Variant
11/30/2021
Quidel Corporation issued the following statement from Douglas Bryant, Quidel’s President and CEO, regarding Quidel’s ongoing efforts to evaluate COVID-19 mutations and confirm that its American-made PCR and antigen tests continue to detect COVID-19 variants such as Omicron.
-
Quidel Presents at 33rd Annual Piper Sandler Healthcare Conference
11/19/2021
Quidel Presents at 33rd Annual Piper Sandler Healthcare Conference.
-
Quidel Reports Third Quarter 2021 Financial Results
11/4/2021
Quidel Corporation announced today financial results for the third quarter ended September 30, 2021.
-
Quidel Corporation to Sponsor Distinguished Speaker Series Conducted by the Bay Area Lyme Foundation
11/2/2021
Quidel Corporation to Sponsor Distinguished Speaker Series Conducted by the Bay Area Lyme Foundation
-
Pediatric Lyme Disease—‘An Epidemic Within a Pandemic!’—to be Focus of Free Webinar Hosted by Quidel Corporation Oct. 21
10/18/2021
Among the many health challenges facing children is the very real threat of contracting Lyme disease as nearly 30% of the estimated 476,000 people in the U.S. each year who are diagnosed and treated for this disease are ages 0-19. In response to this troubling fact, an important webinar focused on how Lyme disease affects the pediatric population will be held on Thursday, Oct. 21.